Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).

Vanesa Gregorc,Alessandra Bulotta,Maria Grazia Viganò,Giovanni Citterio,Giovanna Petrella,Elena Brioschi,Monika Ducceschi,Luca Gianni,Scialini Colombi,G. Rossoni,Giulia Salini,Veronica Savia,A. Lambiase,Claudio Bordignon

Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).

2016

Vanesa Gregorc
Alessandra Bulotta
Maria Grazia Viganò
Giovanni Citterio
Giovanna Petrella
Elena Brioschi
Monika Ducceschi
Luca Gianni
Scialini Colombi
G. Rossoni
Giulia Salini
Veronica Savia
A. Lambiase
Claudio Bordignon

e20077Background: In the NGR015 trial, patients failing a pemetrexed-based regimen were randomly assigned to weekly NGR-hTNF (N; n = 200) or placebo (P; n = 200), both given with BIC that included ...

Keywords:

Physical therapy
Mesothelioma
Placebo
Pathology
Intensive care medicine
NGR-hTNF
Medicine
previously treated
Pemetrexed
double blind
pleural mesothelioma
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations